Best GLP-1 Telehealth Providers in Indianapolis, IN

Telehealth platform specializing in affordable compounded GLP-1 medications for weight loss. Known for aggressive pricing on compounded semaglutide and tirzepatide with fast onboarding.

Major telehealth platform offering GLP-1 weight loss programs with compounded and brand-name semaglutide and tirzepatide. Known for accessible pricing and a streamlined digital experience.

Weight-care platform combining GLP-1 medications with behavior change coaching, nutrition guidance, and community support. Takes a holistic approach beyond medication alone.

Publicly traded (NYSE: HIMS) telehealth company offering GLP-1 weight loss treatments alongside men's and women's health services. Offers both compounded and brand-name GLP-1 options.

Telehealth marketplace connecting patients with licensed doctors for peptide therapy, hormone optimization, and wellness prescriptions. Competitive pricing through network model.

Telehealth platform specializing in weight loss peptides and hormone therapy, known for competitive pricing on GLP-1 medications.

Men's health telehealth platform offering hormone optimization and peptide therapy with at-home lab testing and physician-guided treatment plans.

Large-scale telehealth platform (publicly traded) offering weight management via GLP-1 medications alongside dermatology, hair loss, and primary care services.

Noom started as a behavior-change app focused on psychology-driven weight loss coaching, built around cognitive behavioral therapy (CBT) principles. In 2023, they launched Noom Med, adding GLP-1 prescriptions to their platform. This makes Noom one of the few providers that combines medication with a structured behavioral curriculum — an approach that could help address the weight regain problem associated with GLP-1 discontinuation. The coaching program predates the medication offering by over a

PlushCare is a broad-spectrum telehealth platform offering primary care, mental health, dermatology, and weight management — not a weight-loss-specific company. Acquired by Accolade (publicly traded health services company) in 2021, PlushCare brings the backing of an established healthcare organization. Their generalist model means GLP-1 prescriptions happen within a broader healthcare relationship, and they work extensively with insurance rather than pushing cash-pay compounded medications.

Sequence positions itself as the "clinical-first" GLP-1 telehealth provider. Founded by obesity medicine specialists, the platform emphasizes board-certified clinicians, insurance-first prescribing, and a medically rigorous approach compared to most direct-to-consumer competitors. Their model prioritizes getting patients onto brand-name FDA-approved medications through insurance rather than defaulting to compounded alternatives.

Sesame takes a radically different approach to telehealth GLP-1 access: no subscriptions, no memberships, no monthly fees. You pay per visit, get a prescription if appropriate, and fill it wherever you want. Think of Sesame as the à la carte option — stripped-down, transparent pricing with no ongoing commitments. This model gives patients maximum flexibility but shifts the work of finding affordable medication to the patient.